RU2010141793A - Терапевтические замещенные циклопентаны - Google Patents
Терапевтические замещенные циклопентаны Download PDFInfo
- Publication number
- RU2010141793A RU2010141793A RU2010141793/04A RU2010141793A RU2010141793A RU 2010141793 A RU2010141793 A RU 2010141793A RU 2010141793/04 A RU2010141793/04 A RU 2010141793/04A RU 2010141793 A RU2010141793 A RU 2010141793A RU 2010141793 A RU2010141793 A RU 2010141793A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- pharmaceutically acceptable
- acceptable salt
- compound according
- compound
- Prior art date
Links
- 150000001940 cyclopentanes Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 10
- 201000004384 Alopecia Diseases 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims abstract 2
- 230000003676 hair loss Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
1. Соединение формулы ! ! где Y представляет собой ! или ; ! или его фармацевтически приемлемая соль, ! где пунктирная линия показывает наличие или отсутствие связи. ! 2. Соединение по п.1 формулы ! ! или его фармацевтически приемлемая соль. ! 3. Соединение по п.1 формулы !! или его фармацевтически приемлемая соль. ! 4. Соединение по п.3 формулы ! ! или его фармацевтически приемлемая соль. ! 5. Соединение по п.1 формулы ! ! или его фармацевтически приемлемая соль. ! 6. Способ лечения облысения, включающий введение соединения по п.1 млекопитающему, нуждающемуся в таком лечении.
Claims (6)
1. Соединение формулы
где Y представляет собой
или его фармацевтически приемлемая соль,
где пунктирная линия показывает наличие или отсутствие связи.
2. Соединение по п.1 формулы
или его фармацевтически приемлемая соль.
3. Соединение по п.1 формулы
или его фармацевтически приемлемая соль.
4. Соединение по п.3 формулы
или его фармацевтически приемлемая соль.
5. Соединение по п.1 формулы
или его фармацевтически приемлемая соль.
6. Способ лечения облысения, включающий введение соединения по п.1 млекопитающему, нуждающемуся в таком лечении.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3762508P | 2008-03-18 | 2008-03-18 | |
| US61/037,625 | 2008-03-18 | ||
| US12/404,753 | 2009-03-16 | ||
| US12/404,753 US7732443B2 (en) | 2008-03-18 | 2009-03-16 | Therapeutic substituted cyclopentanes |
| PCT/US2009/037355 WO2009117388A1 (en) | 2008-03-18 | 2009-03-17 | Therapeutic substituted cyclopentanes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010141793A true RU2010141793A (ru) | 2012-04-27 |
| RU2501789C2 RU2501789C2 (ru) | 2013-12-20 |
Family
ID=41089539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010141793/04A RU2501789C2 (ru) | 2008-03-18 | 2009-03-17 | Терапевтические замещенные циклопентаны |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7732443B2 (ru) |
| EP (1) | EP2265576A1 (ru) |
| JP (1) | JP2011515406A (ru) |
| KR (1) | KR20100135264A (ru) |
| CN (1) | CN102007098B (ru) |
| AU (1) | AU2009225706B2 (ru) |
| BR (1) | BRPI0910931A2 (ru) |
| CA (1) | CA2718900A1 (ru) |
| RU (1) | RU2501789C2 (ru) |
| WO (1) | WO2009117388A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569349B2 (en) * | 2008-05-09 | 2013-10-29 | Allergan, Inc. | Therapeutic compounds |
| US8530471B2 (en) * | 2008-05-09 | 2013-09-10 | Allergan, Inc. | Therapeutic cyclopentane derivatives |
| US9090595B2 (en) | 2012-08-27 | 2015-07-28 | Allergan, Inc. | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes |
| CN104684904B (zh) | 2012-08-27 | 2017-10-13 | 阿勒根公司 | 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚 |
| JP6626831B2 (ja) * | 2014-02-20 | 2019-12-25 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少 |
| US9340534B2 (en) * | 2014-07-25 | 2016-05-17 | Allergan, Inc. | Compounds and methods for treating ocular diseases |
| US10329284B2 (en) | 2014-10-02 | 2019-06-25 | Allergan, Inc. | Ester prodrugs of gamma-lactams and their use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4675182A (en) * | 1983-02-12 | 1987-06-23 | Bayer Aktiengesellschaft | Complexes of prostaglandins |
| US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US5698598A (en) | 1995-08-04 | 1997-12-16 | Allergan | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US6090847A (en) | 1997-11-21 | 2000-07-18 | Allergan Sales, Inc. | EP2 -receptor agonists as neuroprotective agents for the eye |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| US6410591B1 (en) * | 2001-05-08 | 2002-06-25 | Allergan Sales, Inc. | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| WO2003040126A1 (en) * | 2001-11-05 | 2003-05-15 | Allergan, Inc. | φ-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS |
| KR101077461B1 (ko) * | 2003-02-11 | 2011-10-26 | 알러간, 인코포레이티드 | 안압 강하제로서의 10,10-디알킬 프로스탄산 유도체 |
| TWI348386B (en) * | 2003-08-12 | 2011-09-11 | R Tech Ueno Ltd | Composition and method for promoting hair growth |
| US7091231B2 (en) * | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
| US7427685B2 (en) * | 2005-12-06 | 2008-09-23 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
| WO2009137345A1 (en) * | 2008-05-09 | 2009-11-12 | Allergan, Inc. | Therapeutic compounds |
-
2009
- 2009-03-16 US US12/404,753 patent/US7732443B2/en not_active Expired - Fee Related
- 2009-03-17 JP JP2011500890A patent/JP2011515406A/ja active Pending
- 2009-03-17 CN CN200980113565.8A patent/CN102007098B/zh not_active Expired - Fee Related
- 2009-03-17 RU RU2010141793/04A patent/RU2501789C2/ru not_active IP Right Cessation
- 2009-03-17 AU AU2009225706A patent/AU2009225706B2/en not_active Expired - Fee Related
- 2009-03-17 CA CA2718900A patent/CA2718900A1/en not_active Abandoned
- 2009-03-17 WO PCT/US2009/037355 patent/WO2009117388A1/en active Application Filing
- 2009-03-17 BR BRPI0910931A patent/BRPI0910931A2/pt not_active IP Right Cessation
- 2009-03-17 EP EP09723041A patent/EP2265576A1/en not_active Withdrawn
- 2009-03-17 KR KR1020107023241A patent/KR20100135264A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2501789C2 (ru) | 2013-12-20 |
| AU2009225706B2 (en) | 2014-07-31 |
| CN102007098B (zh) | 2014-05-07 |
| AU2009225706A1 (en) | 2009-09-24 |
| BRPI0910931A2 (pt) | 2019-09-24 |
| US7732443B2 (en) | 2010-06-08 |
| KR20100135264A (ko) | 2010-12-24 |
| CA2718900A1 (en) | 2009-09-24 |
| EP2265576A1 (en) | 2010-12-29 |
| CN102007098A (zh) | 2011-04-06 |
| JP2011515406A (ja) | 2011-05-19 |
| US20090239869A1 (en) | 2009-09-24 |
| WO2009117388A1 (en) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| RU2010141793A (ru) | Терапевтические замещенные циклопентаны | |
| EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
| EA201290416A1 (ru) | Новые спиропиперидиновые соединения | |
| UA107652C2 (en) | Carbazole compounds and therapeutic uses of the compounds | |
| EA201270560A1 (ru) | Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета | |
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| EA201170521A1 (ru) | Новые соединения | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| EA201071264A1 (ru) | Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера | |
| EA200970935A1 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| EA201270247A1 (ru) | Способы применения с-мет-модуляторов | |
| RU2012140185A (ru) | Ингибирование ангиогенеза | |
| EA201490493A1 (ru) | Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы | |
| EA201071099A1 (ru) | СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR | |
| EA201390626A1 (ru) | Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций | |
| EA200702363A1 (ru) | Новые лиганды гистамина h-рецептора и их терапевтические применения | |
| EA201490269A1 (ru) | Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета | |
| EA201170154A1 (ru) | Производные пиридинопиридинонов, способ их получения и применение в терапии | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| UA107562C2 (uk) | Спосіб лікування псоріазу |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150318 |